Response/NN
to/TO
intranasal/JJ
fluticasone/NN
propionate/NN
in/IN
perennial/JJ
allergic/JJ
rhinitis/NN
not/RB
associated/VBN
with/IN
glucocorticoid/NN
receptor/NN
characteristics/NNS
./.

BACKGROUND/NN
:/:
The/DT
reduction/NN
of/IN
symptoms/NNS
due/JJ
to/TO
treatment/NN
with/IN
corticosteroids/NNS
varies/VBZ
among/IN
patients/NNS
with/IN
perennial/JJ
rhinitis/NN
./.
=====
Most/JJS
patients/NNS
will/MD
respond/VB
but/CC
a/DT
few/JJ
patients/NNS
respond/VBP
less/RBR
to/TO
these/DT
drugs/NNS
./.
=====
OBJECTIVE/NN
:/:
To/TO
investigate/VB
the/DT
association/NN
in/IN
reduction/NN
of/IN
symptoms/NNS
due/JJ
to/TO
glucocorticoids/NNS
and/CC
glucocorticoid/NN
receptor/NN
characteristics/NNS
in/IN
patients/NNS
with/IN
perennial/JJ
allergic/JJ
rhinitis/NN
,/,
in/FW
vitro/FW
glucocorticoid/NN
receptor/NN
binding/NN
studies/NNS
were/VBD
performed/VBN
with/IN
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
using/VBG
dexamethasone/NN
and/CC
in/FW
vitro/FW
production/NN
of/IN
mediators/NNS
were/VBD
measured/VBN
./.
=====
METHODS/NNS
:/:
During/IN
a/DT
double-blind/JJ
placebo-controlled/JJ
crossover/JJ
study/NN
,/,
200/CD
micrograms/NNS
fluticasone/NN
propionate/JJ
aqueous/JJ
nasal/JJ
spray/NN
(/(
in/IN
the/DT
active/JJ
treatment/NN
period/NN
)/)
and/CC
placebo/NN
(/(
in/IN
the/DT
placebo/NN
treatment/NN
period/NN
)/)
were/VBD
administered/VBN
twice/RB
daily/RB
for/IN
2/CD
weeks/NNS
to/TO
22/CD
patients/NNS
allergic/JJ
to/TO
house/NN
dust/NN
mite/NN
./.
=====
At/IN
the/DT
end/NN
of/IN
both/DT
treatment/NN
periods/NNS
symptoms/NNS
were/VBD
scored/VBN
after/IN
allergen/NN
provocation/NN
(/(
100/CD
,/,
1000/CD
,/,
10000/CD
BU/mL/NN
)/)
and/CC
during/IN
the/DT
9.5/CD
hours/NNS
after/IN
this/DT
challenge/NN
./.
=====
Receptor/NN
binding/NN
studies/NNS
with/IN
dexamethasone/NN
were/VBD
performed/VBN
with/IN
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
./.
=====
Leukotriene/NN
B4/NN
produced/VBN
by/IN
monocytes/NNS
in/FW
vitro/FW
and/CC
soluble/JJ
interleukin-2/NN
receptor/NN
released/VBN
by/IN
lymphocytes/NNS
in/FW
vitro/FW
and/CC
cortisol/NN
levels/NNS
in/IN
plasma/NN
were/VBD
determined/VBN
./.
=====
RESULTS/NNS
:/:
No/DT
significant/JJ
partial/JJ
correlations/NNS
of/IN
the/DT
number/NN
of/IN
the/DT
peripheral/JJ
blood/NN
mononuclear/JJ
cell/NN
glucocorticoid/NN
receptors/NNS
(/(
6821/CD
+/-/CC
5669/CD
binding/VBG
sites/NNS
per/IN
cell/NN
)/)
and/CC
the/DT
affinity/NN
(/(
Kd/NN
:/:
16.5/CD
+/-/CC
13.51/CD
nmol/L/NN
)/)
for/IN
the/DT
glucocorticoid/NN
receptors/NNS
with/IN
the/DT
symptom/NN
score/NN
(/(
placebo/NN
:/:
4.3/CD
+/-/CC
2.45/CD
pts/NNS
;/:
fluticasone/NN
:/:
2.4/CD
+/-/CC
1.55/CD
pts/NNS
)/)
after/IN
active/JJ
treatment/NN
were/VBD
found/VBN
./.
=====
Also/RB
no/DT
significant/JJ
partial/JJ
correlations/NNS
of/IN
the/DT
levels/NNS
of/IN
leukotriene/NN
B4/NN
(/(
45.6/CD
+/-/CC
105.3/CD
ng/10(6)/CD
cells/NNS
)/)
produced/VBN
by/IN
monocytes/NNS
in/FW
vitro/FW
,/,
soluble/JJ
interleukin-2/NN
receptor/NN
(/(
734/CD
+/-/CC
237/CD
ng/10(6)/CD
cells/NNS
)/)
released/VBN
by/IN
lymphocytes/NNS
in/FW
vitro/FW
and/CC
cortisol/NN
levels/NNS
(/(
571/CD
+/-/CC
236/CD
ng/mL/NN
)/)
in/IN
plasma/NN
with/IN
the/DT
symptom/NN
score/NN
after/IN
active/JJ
treatment/NN
were/VBD
found/VBN
./.
=====
CONCLUSIONS/NNS
:/:
The/DT
reduction/NN
of/IN
symptoms/NNS
due/JJ
to/TO
topical/JJ
fluticasone/NN
propionate/NN
in/IN
patients/NNS
with/IN
rhinitis/NN
and/CC
allergy/NN
to/TO
house/NN
dust/NN
mite/NN
is/VBZ
not/RB
correlated/VBN
with/IN
the/DT
characteristics/NNS
of/IN
the/DT
glucocorticoid/NN
receptor/NN
./.